Ask the Experts: aducanumab

Written by The Evidence Base

ATE aducanumab

In this ‘Ask the Experts’ feature, we’ve brought together a panel of key thought leaders to discuss the Alzheimer’s drug aducanumab. The drug was approved for use by the US FDA in June 2021, a decision that caused much debate within the neuroscience community. To what extent has amyloid been shown to be a causative characteristic of Alzheimer’s? Does – and should – the ‘patient voice’ play a role in these kind of approval decisions? How may this approval impact future Alzheimer’s drug approvals? Our experts for this feature include Robert Howard (University College London; UK), Mark Dallas (University of Reading; UK) and David Whitrap (Institute for...

To view this content, please register now for access

It's completely free